#United States #Los Angeles #DJS Law Group #Soleno Therapeutics #SLNO

Class Action Lawsuit Against Soleno Therapeutics

Soleno Therapeutics, Inc. is facing a class action lawsuit that raises concerns for investors who purchased shares in the company during a specified class period. According to the DJS Law Group, the firm leading the case, Soleno has allegedly violated key provisions of the Securities Exchange Act of 1934. The lawsuit is focused primarily on the company’s misleading public statements regarding its clinical trials and overall business status.

Background of the Case

From March 26, 2025, to November 4, 2025, shareholders claim that Soleno provided false and misleading information related to the safety and commercial viability of its drug candidate, diazoxide choline extended-release tablets (DCCR). The alleged misrepresentations led investors to make decisions based on information that did not accurately reflect the risks associated with Soleno's clinical results.

Allegations of Misleading Statements

As outlined in the complaint, Soleno purportedly downplayed safety concerns discovered during its Phase 3 trials of DCCR. This negligence not only affected investor sentiment but also significantly impacted the drug's market viability. It raises the question of whether Soleno may have acted unethically by not fully disclosing potential risks associated with its treatments.

Who Can Participate?

The DJS Law Group is currently inviting any individual who purchased shares of Soleno during the class period to reach out for potential lead plaintiff appointments. Importantly, being appointed as a lead plaintiff is not necessary for investors who wish to participate in any recovery from the lawsuit. The deadline for filing claims or joining the case is set for May 5, 2026.

What Should Investors Do?

Investors affected by Soleno's alleged actions are urged to consider participating in the lawsuit to recover their losses. The DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on the interests of investors to ensure they receive fair representation. The firm emphasizes that protecting investors’ interests is their top priority and highlights that failure to respond could diminish the chance of recouping any financial losses incurred during this period.

Why Choose DJS Law Group?

With a proven track record in handling complex securities litigation, the DJS Law Group has effectively represented numerous high-profile clients, including hedge funds and alternative asset managers. Their commitment to aggressive advocacy paired with balanced legal counsel sets them apart in the field. This case is portrayed not just as a lawsuit, but as an opportunity for investors to hold the company accountable for its alleged misconduct and potentially restore their financial standing.

Final Thoughts

The ongoing situation surrounding Soleno Therapeutics and the class action lawsuit serves as a crucial reminder for investors to remain vigilant about the companies in which they invest. Transparency and accountability are essential in maintaining the integrity of the financial markets. Investors are encouraged to stay informed and consider their options, especially in light of potential legal recourse if they feel deceived by the company's statements.

If you believe you have a valid claim against Soleno Therapeutics, reach out to DJS Law Group to discuss your rights and avenues for recovery. This could be an important step in safeguarding your investment.

For more information about the lawsuit or to get in touch with the DJS Law Group, refer to their contact details provided in the press release.